Patents by Inventor Andrew James Pow

Andrew James Pow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST TL1A AND USES THEREOF
    Publication number: 20240141053
    Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
    Type: Application
    Filed: April 20, 2023
    Publication date: May 2, 2024
    Inventors: Lynn Dorothy POULTON, Adam CLARKE, Andrew James POW, Debra TAMVAKIS, George KOPSIDAS, Anthony Gerard DOYLE, Philip Anthony JENNINGS, Matthew POLLARD
  • ANTIBODIES AGAINST TL1A AND USES THEREOF
    Publication number: 20210347904
    Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
    Type: Application
    Filed: September 24, 2020
    Publication date: November 11, 2021
    Inventors: Lynn Dorothy POULTON, Adam CLARKE, Andrew James POW, Debra TAMVAKIS, George KOPSIDAS, Anthony Gerard DOYLE, Philip Anthony JENNINGS, Matthew POLLARD
  • Antibodies against TL1a and uses thereof
    Patent number: 10822422
    Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: November 3, 2020
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
  • Antibodies Against TL1a and Uses Thereof
    Publication number: 20160333104
    Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
    Type: Application
    Filed: July 11, 2016
    Publication date: November 17, 2016
    Inventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
  • ANTI-IL-12/IL-23 ANTIBODIES
    Publication number: 20160264661
    Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.
    Type: Application
    Filed: April 22, 2016
    Publication date: September 15, 2016
    Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Hoi Yi Wai, Andrew James Pow, George Kopsidas
  • ANTIBODIES TO CD1d
    Publication number: 20140286957
    Abstract: Isolated antibodies or antigen binding portions thereof that bind to CD1d. These antibodies and antigen binding portions thereof have application in treatment of conditions involving NKT cell effector function.
    Type: Application
    Filed: April 10, 2014
    Publication date: September 25, 2014
    Applicant: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Jonathan Kannan Nambiar, Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Matthew Pollard, Huseyin Mustafa
  • ANTIBODIES AGAINST TL1a AND USES THEREOF
    Publication number: 20140255302
    Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
    Type: Application
    Filed: March 28, 2014
    Publication date: September 11, 2014
    Applicant: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
  • ANTI-IL-12/IL-23 ANTIBODIES
    Publication number: 20140086922
    Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.
    Type: Application
    Filed: September 18, 2013
    Publication date: March 27, 2014
    Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
  • Anti-IL-12/IL-23 antibodies
    Patent number: 8563697
    Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: October 22, 2013
    Assignee: Cephalon Australia Pty. Ltd.
    Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
  • ANTI-IL-12/IL-23 ANTIBODIES
    Publication number: 20110262445
    Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.
    Type: Application
    Filed: August 14, 2009
    Publication date: October 27, 2011
    Applicant: CEPHALON AUSTRALIA PTY LTD.
    Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow